Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. 詳細を表示
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline PR Newswire PHILADELPHIA, Dec. 9, 2024 Resources realigned to focus primarily on in vivo macrophage engineering...
Regulatory News: CARMILA (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto- détenues) Nombre théorique de droits de...
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference PR Newswire PHILADELPHIA, Nov. 27, 2024 PHILADELPHIA, Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics...
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 PR Newswire PHILADELPHIA, Nov. 17, 2024...
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR Newswire PHILADELPHIA, Nov. 8, 2024 New findings showcase the potential of in vivo...
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, Nov. 7, 2024 Initial results from the Phase 1 study of CT-0525, lead...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.039 | -8.90410958904 | 0.438 | 0.4963 | 0.3809 | 356929 | 0.43885241 | CS |
| 4 | -0.451 | -53.0588235294 | 0.85 | 0.888094 | 0.3809 | 373573 | 0.55253623 | CS |
| 12 | -0.5686 | -58.7639520463 | 0.9676 | 1.13 | 0.3809 | 220862 | 0.74426678 | CS |
| 26 | -0.621 | -60.8823529412 | 1.02 | 1.7 | 0.3809 | 300687 | 1.06368255 | CS |
| 52 | -2.651 | -86.9180327869 | 3.05 | 3.16 | 0.3809 | 233814 | 1.37536195 | CS |
| 156 | -5.391 | -93.1088082902 | 5.79 | 9.7662 | 0.3809 | 237636 | 3.17856376 | CS |
| 260 | -5.391 | -93.1088082902 | 5.79 | 9.7662 | 0.3809 | 237636 | 3.17856376 | CS |
PonkenPlonken
3月前
jondoeuk
3月前
Prestotic
4月前
Prestotic
4月前
Prestotic
4月前
Prestotic
4月前
Prestotic
4月前
Prestotic
4月前
CancunCharlie
5月前
PonkenPlonken
6月前
glenn1919
6月前
Awl416
6月前
Termite7
7月前
axelvento
7月前
PonkenPlonken
8月前
Monksdream
9月前
mrplmer
1年前
mrplmer
1年前
81vette
1年前
81vette
1年前
stock1ace1
1年前
81vette
1年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
